Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 3
2017 1
2018 3
2019 1
2021 4
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Broadly neutralizing antibodies in HIV-1 treatment and prevention.
Kumar R, Qureshi H, Deshpande S, Bhattacharya J. Kumar R, et al. Among authors: deshpande s. Ther Adv Vaccines Immunother. 2018 Oct 12;6(4):61-68. doi: 10.1177/2515135518800689. eCollection 2018 Aug. Ther Adv Vaccines Immunother. 2018. PMID: 30345419 Free PMC article. Review.
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.
Hingankar N, Deshpande S, Das P, Rizvi ZA, Wibmer CK, Mashilo P, Ansari MY, Burns A, Barman S, Zhao F, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Dandotiya J, Bhattacharyya S, Mani S, Samal S, Singh S, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshi G, Ward AB, Bhatnagar S, Awasthi A, Sok D, Bhattacharya J. Hingankar N, et al. Among authors: deshpande s. PLoS Pathog. 2022 Apr 28;18(4):e1010465. doi: 10.1371/journal.ppat.1010465. eCollection 2022 Apr. PLoS Pathog. 2022. PMID: 35482816 Free PMC article.
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava T, Samal S, Rathna Murugesan D, Koundinya Desiraju B, Kshetrapal P, Pandey R, Scaria V, Kumar Malik P, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Ahmad Khan N, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vrati S, Bhatnagar S, Garg PK; Department of Biotechnology India Consortium for COVID-19 research. Thiruvengadam R, et al. Among authors: deshpande s. Lancet Infect Dis. 2022 Apr;22(4):473-482. doi: 10.1016/S1473-3099(21)00680-0. Epub 2021 Nov 25. Lancet Infect Dis. 2022. PMID: 34838183 Free PMC article.
Elicitation of potent serum neutralizing antibody responses in rabbits by immunization with an HIV-1 clade C trimeric Env derived from an Indian elite neutralizer.
Kumar R, Deshpande S, Sewall LM, Ozorowski G, Cottrell CA, Lee WH, Holden LG, Richey ST, Chandrawacar AS, Dhiman K, Ashish, Kumar V, Ahmed S, Hingankar N, Kumar N, Murugavel KG, Srikrishnan AK, Sok D, Ward AB, Bhattacharya J. Kumar R, et al. Among authors: deshpande s. PLoS Pathog. 2021 Apr 7;17(4):e1008977. doi: 10.1371/journal.ppat.1008977. eCollection 2021 Apr. PLoS Pathog. 2021. PMID: 33826683 Free PMC article.
Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
Mullick R, Sutar J, Hingankar N, Deshpande S, Thakar M, Sahay S, Ringe RP, Mukhopadhyay S, Patil A, Bichare S, Murugavel KG, Srikrishnan AK, Goyal R, Sok D, Bhattacharya J. Mullick R, et al. Among authors: deshpande s. Retrovirology. 2021 May 14;18(1):12. doi: 10.1186/s12977-021-00556-2. Retrovirology. 2021. PMID: 33990195 Free PMC article.
14 results